LIXT Short Volume

Lixte Biotechnology Holdings, Inc. (LIXT) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $79.5M, listed on NASDAQ, employing roughly 2 people, carrying a beta of 1.05 to the broader market. Lixte Biotechnology Holdings, Inc. Led by Geordan G. Pursglove, public since 2007-10-25.

Short volume measures the number of shares sold short on a given day as reported by FINRA. Tracking short volume relative to total volume helps identify unusual bearish sentiment or short-squeeze potential.

Latest Date
2026-06-01
Short Volume
70.8K
Total Volume
157.4K
Short %
44.97%
30-Day Avg Short %
32.79%

Showing 30 days of FINRA short volume data for Lixte Biotechnology Holdings, Inc..

Learn how short volume is reported and how to read the data →

Frequently asked LIXT short volume questions

What is the daily LIXT short volume?
As of Jun 1, 2026, Lixte Biotechnology Holdings, Inc. (LIXT) short volume is 70.8K shares against 157.4K total reported volume, or 44.97% short-side. Short volume measures shares sold short during the day; it is flow, not inventory.
How is LIXT short volume reported?
FINRA publishes the Daily Short Sale Volume File for trades reported to FINRA TRFs and the FINRA/Nasdaq ADF on a T+1 basis. The headline figure is the count of shares that printed at the short-sale or short-exempt tick across all reporting venues for the symbol; each exchange separately publishes its own daily short-sale data file.
What does LIXT short volume tell options traders?
Daily short-sale flow is one input that helps disambiguate dealer-hedging activity from directional bear flow when the chain shows fresh customer call inventory. It is not a clean MM-only proxy: the headline number mixes directional shorting, options-MM delta-hedging, ETF-creation arbitrage, and convertible-arb hedging. Cross-check against gamma-exposure and OI changes for a cleaner read.